---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-011514"
form_type: "8-K"
ticker: "CELC"
cik: "0001603454"
company_name: "Celcuity Inc."
filed_at: "2024-03-27T23:59:59+00:00"
generated_at: "2026-06-04T07:10:17.024392+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Celcuity Q4 net loss $18.8M; FY net loss $63.8M; cash into H1 2026; VIKTORIA-1 topline data H2 2024

## Summary
- Net loss Q4 2023 $18.8M ($0.65 loss per share) vs $11.6M ($0.69) in Q4 2022.
- Full year 2023 net loss $63.8M ($2.69 per share) vs $40.4M ($2.64) in 2022.
- Raised $65M from equity sale; cash expected to fund operations into first half of 2026.
- Phase 3 VIKTORIA-1 trial on track to report topline data for PIK3CA wild type subgroup H2 2024.
- First patient dosed in Phase 1b/2 trial of gedatolisib + darolutamide for mCRPC in February 2024.

## SEC filing metadata
- accession: 0001493152-24-011514
- form_type: 8-K
- ticker: CELC
- cik: 0001603454
- company_name: Celcuity Inc.
- filed_at: 2024-03-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1603454/000149315224011514/0001493152-24-011514-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1603454/000149315224011514/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-011514
- JSON: https://secwatch.observer/filing/0001493152-24-011514.json
- Plain text: https://secwatch.observer/filing/0001493152-24-011514.txt

## Key facts
- Earnings Releases
  Celcuity Inc. reported the fourth quarter and fiscal year ended December 31, 2023 results: net income Net loss for the fourth quarter of 2023 was $18.8 million, or $0.65 loss per share, compared to a net loss of $11.6 mill, EPS $0.65 loss per share.
  - Period: the fourth quarter and fiscal year ended December 31, 2023
  - Net income: Net loss for the fourth quarter of 2023 was $18.8 million, or $0.65 loss per share, compared to a net loss of $11.6 mill
  - EPS: $0.65 loss per share
  - Result: reported results
  source text: Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced financial results for the fourth quarter and full year ended December 31, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1603454/000149315224011514/0001493152-24-011514-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.